- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07301255
ENV-294 til moderat til svær astma: Et 12-ugers studie hos voksne
En fase 2, randomiseret, dobbeltblind, placebo-kontrolleret, parallel-gruppe, 12-ugers undersøgelse for at evaluere effektiviteten, sikkerheden og farmakokinetikken af ENV-294 hos voksne deltagere med moderat til svær astma
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA).
Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.
Studieoversigt
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
- Navn: Clinical Operations
- E-mail: env-294.clinicaltrials@enveda.com
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35209
- Rekruttering
- Enveda Investigative Site
-
-
California
-
Los Angeles, California, Forenede Stater, 90025
- Rekruttering
- Enveda Investigative Site
-
San Jose, California, Forenede Stater, 95117
- Rekruttering
- Enveda Investigative Site
-
West Hills, California, Forenede Stater, 91307
- Rekruttering
- Enveda Investigative Site
-
-
Colorado
-
Colorado Springs, Colorado, Forenede Stater, 80907
- Rekruttering
- Enveda Investigative Site
-
-
Florida
-
Hialeah, Florida, Forenede Stater, 33012
- Rekruttering
- Enveda Investigative Site
-
Miami, Florida, Forenede Stater, 33135
- Rekruttering
- Enveda Investigative Site
-
-
Georgia
-
Albany, Georgia, Forenede Stater, 31707
- Rekruttering
- Enveda Investigative Site
-
-
Illinois
-
Maryville, Illinois, Forenede Stater, 62062
- Rekruttering
- Enveda Investigative Site
-
-
Kansas
-
Kansas City, Kansas, Forenede Stater, 66160
- Rekruttering
- Enveda Investigative Site
-
-
Kentucky
-
Owensboro, Kentucky, Forenede Stater, 42301
- Rekruttering
- Enveda Investigative Site
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Rekruttering
- Enveda Investigative Site
-
-
Michigan
-
Southfield, Michigan, Forenede Stater, 48075
- Rekruttering
- Enveda Investigative Site
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63141
- Rekruttering
- Enveda Investigative Site
-
-
New York
-
The Bronx, New York, Forenede Stater, 10455
- Rekruttering
- Enveda Investigative Site
-
-
Oregon
-
Clackamas, Oregon, Forenede Stater, 97015
- Rekruttering
- Enveda Investigative Site
-
Medford, Oregon, Forenede Stater, 97504
- Rekruttering
- Enveda Investigative Site
-
-
South Carolina
-
North Charleston, South Carolina, Forenede Stater, 29406
- Rekruttering
- Enveda Investigative Site
-
-
Texas
-
McKinney, Texas, Forenede Stater, 75069
- Rekruttering
- Enveda Investigative Site
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- Rekruttering
- Enveda Investigative Site
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Able to read, understand, and sign an informed consent form before any study procedures
- Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months
- Receiving stable treatment with an inhaled corticosteroid (ICS) plus a long-acting beta₂-agonist (LABA) for at least 2 months before screening
- Pre-bronchodilator FEV₁ between 50% and 80% of predicted normal at screening and baseline
- Demonstrated bronchodilator reversibility
- ACQ-5 score ≥1.25 to ≤3.0 at screening and baseline
- History of at least one asthma exacerbation in the past 12 months requiring systemic corticosteroids or hospitalization/emergency care
Exclusion Criteria:
- Recent moderate or severe asthma exacerbation (within 4 weeks before screening)
- History of life-threatening asthma
- Other significant pulmonary disease
- Recent bronchial thermoplasty (within 2 years)
- Uncontrolled current or recurrent concomitant illness
- Recent use of biologic therapies for asthma (within 6 months or 5 half-lives)
- Require immunosuppressive medications or frequent systemic corticosteroids
- Current smokers or former smokers with significant smoking history
- Uncontrolled hypertension
- Significant hepatic impairment
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: ENV-294 Treatment Arm
ENV-294 will be administered to those participants randomized to the treatment arm. |
ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks. |
|
Placebo komparator: Placebo Arm
A placebo will be administered to those participants randomized to the placebo arm. |
Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence and Severity of Adverse Events
Tidsramme: From first dose through approximately 16 weeks
|
Number and percentage of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuation of study drug. |
From first dose through approximately 16 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Loss of Asthma Control Events
Tidsramme: Baseline to Week 12
|
Number and percentage of participants experiencing a loss of asthma control (LOAC) event during the treatment period, defined according to protocol-specified criteria |
Baseline to Week 12
|
|
Time to Loss of Asthma Control
Tidsramme: Baseline to Week 12
|
Time from the first dose of study drug to the first occurrence of a loss of asthma control (LOAC) event, as defined in the protocol. |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
Tidsramme: Baseline to Week 12
|
Change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV₁), measured using standardized spirometry. |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
Tidsramme: Baseline to Week 12
|
Change from Baseline in the Asthma Control Questionnaire (ACQ-5) |
Baseline to Week 12
|
|
To assess the efficacy of ENV-294 in participants with asthma
Tidsramme: Baseline to Week 12
|
Change from Baseline in the Asthma Quality of Life Questionnaire (AQLQ) |
Baseline to Week 12
|
|
Plasma concentration of ENV-294
Tidsramme: Baseline to Week 12
|
Plasma concentrations of ENV-294 will be measured at specified time points following oral administration of the investigational drug. |
Baseline to Week 12
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Gurpreet Ahluwalia, PhD, Enveda Therapeutics, Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- ENV-294-211
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data (IPD) will not be shared. The data include sensitive health information that cannot be fully de-identified under current privacy standards, and the sponsor does not plan to make IPD available outside the study team. Summary results and aggregate data will be shared publicly as required by regulation.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .